Cybin (NEO: CYBN) (OTCQB: CLXPF) announced changes in senior management positions. Cybin US Holdings Inc.’s new chief clinical officer will be Alexander Belser, PhD and its new chief operating officer will be Aaron Bartlone. In addition, co-founder and former COO Paul Glavine has been named chief growth officer and co-founder of Cybin Inc., while former SVP of business development John Kanakis will become chief business officer. The changes are effective immediately. An accomplished biopharmaceutical executive with a proven track record across numerous therapeutic and functional areas, Bartlone has extensive experience with quality assurance, regulatory affairs, product development, compliance and commercial operations. A well-known leader in the field of psychedelic research, Belser has served as an investigator on clinical trials of psilocybin and MDMA to treat depression, anxiety, substance use, obsessive-compulsive disorder (“OCD”), post-traumatic stress disorder (“PTSD”), and end-of-life distress at New York University and Yale University. “We are committed to building our presence both in the United States and in Europe to advance our mission of improving mental healthcare through therapeutic development programs and innovative drug delivery systems,” said Cybin CEO Doug Drysdale in the press release. “These appointments will serve to strengthen our development and clinical operations globally and solidify Cybin’s position within the industry. Alex and Aaron bring deep clinical, commercial and regulatory expertise that will serve to broaden our management and scientific leadership teams. We look forward to their contributions as we pursue increased visibility across these additional markets. Paul and John’s extensive entrepreneurial experience was instrumental in shaping the initial formation of Cybin and the company’s subsequent emergence as a leader within the psychedelics space. Their deep commitment to Cybin’s mission will continue as they assume these new roles and will allow them to further accelerate business development and investor awareness initiatives. We believe these appointments are an important step in taking Cybin to the next level.”
To view the full press release, visit https://ibn.fm/N8xj7
About Cybin Inc.
Cybin Corp. (NEO: CBYN; OTC: CLXPF) is a leading biotech company focused on progressing psychedelic therapeutics. Cybin is on a mission to revolutionize mental healthcare. Cybin is focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
